Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C L Slingluff

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 5, 2000
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cellsH M Zarour, J M Kirkwood, L S Kierstead, et al.
Science (New York, N.Y.)|April 29, 1994
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell linesA L Cox, J Skipper, Y Chen, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|September 2, 1998
Complete spontaneous regression of pulmonary metastatic melanomaT S Wang, L Lowe, J W Smith, et al.
International Journal of Cancer|September 25, 1999
Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccinesL H Brinckerhoff, V V Kalashnikov, L W Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2001
Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluationsG Yamshchikov, L Thompson, W G Ross, et al.
International Journal of Cancer|July 27, 1999
Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100J C Skipper, P H Gulden, R C Hendrickson, et al.
The Journal of Experimental Medicine|January 31, 1998
The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosolC A Mosse, L Meadows, C J Luckey, et al.
British Journal of Cancer|December 18, 2001
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cellsL S Kierstead, E Ranieri, W Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Patient preferences for adjuvant interferon alfa-2b treatmentK L Kilbridge, J C Weeks, A J Sober, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1996
Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100J C Skipper, D J Kittlesen, R C Hendrickson, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Proceedings of the National Academy of Sciences of the United States of America|January 5, 2000
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cellsH M Zarour, J M Kirkwood, L S Kierstead, et al.
Science (New York, N.Y.)|April 29, 1994
Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell linesA L Cox, J Skipper, Y Chen, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|September 2, 1998
Complete spontaneous regression of pulmonary metastatic melanomaT S Wang, L Lowe, J W Smith, et al.
International Journal of Cancer|September 25, 1999
Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccinesL H Brinckerhoff, V V Kalashnikov, L W Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2001
Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluationsG Yamshchikov, L Thompson, W G Ross, et al.
International Journal of Cancer|July 27, 1999
Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100J C Skipper, P H Gulden, R C Hendrickson, et al.
The Journal of Experimental Medicine|January 31, 1998
The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosolC A Mosse, L Meadows, C J Luckey, et al.
British Journal of Cancer|December 18, 2001
gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cellsL S Kierstead, E Ranieri, W Olson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2001
Patient preferences for adjuvant interferon alfa-2b treatmentK L Kilbridge, J C Weeks, A J Sober, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 1, 1996
Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100J C Skipper, D J Kittlesen, R C Hendrickson, et al.
Pageof 6